Aileron Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
RNTX$0.59-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $— | $— |
| Operating expenses: | ||
| Research and development | 3,463 | 1,810 |
| General and administrative | 3,742 | 2,179 |
| Restructuring and other costs | — | 1,022 |
| Total operating expenses | 7,205 | 5,011 |
| Loss from operations | (7,205) | (5,011) |
| Other income, net | 92 | 232 |
| Net loss | $(7,113) | $(4,779) |
| Net loss per share—basic and diluted | $(0.86) | $(1.05) |
| Weighted average common shares outstanding—basic and diluted | 8,301,798 | 4,541,167 |
| Comprehensive loss: | ||
| Net loss | $(7,113) | $(4,779) |
| Other comprehensive gain: | ||
| Unrealized gain on investments, net of tax of $0 | — | 38 |
| Total other comprehensive gain | — | 38 |
| Total comprehensive loss | $(7,113) | $(4,741) |
Condensed Consolidated STATEMENT OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
(In thousands, except share data)
| Convertible Series X Preferred Stock · Common Stock · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Additional Paid-inCapital | AccumulatedOther ComprehensiveLoss | AccumulatedDeficit | Convertible Preferred Stock and Stockholders’Equity | |
| Balances at December 31, 2023 | 24,610 | $91,410 | 4,885,512 | $91 | $295,376 | $(63) | $(288,517) | $98,297 |
| Issuance of common stock in connection with conversion of Series X preferred stock | (11,957) | (44,826) | 11,957,000 | 12 | 44,814 | — | — | — |
| Stock-based compensation expense | — | — | — | — | 150 | — | — | 150 |
| Net loss | — | — | — | — | — | — | (7,113) | (7,113) |
| Balances at March 31, 2024 | 12,653 | $46,584 | 16,842,512 | $103 | $340,340 | $(63) | $(295,630) | $91,334 |
| Balances at December 31, 2022 | — | $— | 4,541,167 | $91 | $291,365 | $(48) | $(272,785) | $18,623 |
| Stock-based compensation expense | — | — | — | — | 391 | — | — | 391 |
| Unrealized loss on investments | — | — | — | — | — | 38 | — | 38 |
| Net loss | — | — | — | — | — | — | (4,779) | (4,779) |
| Balances at March 31, 2023 | — | $— | 4,541,167 | $91 | $291,756 | $(10) | $(277,564) | $14,273 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.